Cell-free mitochondrial DNA deletions in idiopathic, but not LRRK2, Parkinson's disease

• Published in: Neurobiology of disease 2022-11, Vol.174, p.105885-105885, Article 105885
• Main Authors: Puigròs, Margalida, Calderon, Anna, Pérez-Soriano, Alexandra, de Dios, Cristina, Fernández, Manel, Colell, Anna, Martí, Maria-José, Tolosa, Eduardo, Trullas, Ramon
• Format: Article
• Language: English
• Subjects: Digital PCR; LRRK2; Mitochondrial DNA; Mitochondrial DNA deletions; Parkinson's disease
• ISSN: 0969-9961; 1095-953X
• DOI: 10.1016/j.nbd.2022.105885

Mitochondrial dysfunction happens in both idiopathic (iPD) and LRRK2-related Parkinson's disease (LRRK2-PD). Nonetheless, previous studies suggested that a different type of mitochondrial pathology underlies the neurodegeneration in these two disorders. To further explore this hypothesis, we developed a novel multiplex digital PCR assay that allows the absolute quantification of cell-free mitochondrial DNA (cf-mtDNA) copy number and deletion ratio directly in cerebrospinal fluid (CSF) by simultaneously measuring two opposed regions of the mtDNA circular molecule, one of them in the commonly deleted major arc. The results confirmed that the content of cf-mtDNA in CSF was statistically significantly different between iPD and LRRK2-PD patients. Moreover, we found high cf-mtDNA deletion levels in CSF from patients with iPD, but not LRRK2-PD. The high cf-mtDNA deletion frequency in iPD was validated in an independent cohort. These results indicated that the content and deletion ratio of cf-mtDNA may differentiate iPD from LRRK2-PD, and provides further evidence of the different mitochondrial pathophysiology between these two forms of the disease. •Quantification of cell-free mitochondrial DNA deletions in cerebrospinal fluid.•High content of integral cell-free mitochondrial DNA in LRRK2 Parkinson's disease.•High cell-free mitochondrial DNA deletions in idiopathic Parkinson's disease.